Intranasal Saline May Suffice for Some Kids' Sleep-Disordered Breathing
(MedPage Today) -- Intranasal mometasone furoate was no better than saline for resolving symptoms of sleep-disordered breathing (SDB) in children, but either treatment may reduce the need for specialty care or surgery, the randomized MIST trial... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - January 18, 2023 Category: Psychiatry Source Type: news
New Nasal Spray for Seasonal Allergic Rhinitis New Nasal Spray for Seasonal Allergic Rhinitis
Patients with both nasal and ocular symptoms of SAR have a new treatment option that combines olopatadine hydrochloride and mometasone furoate in the form of a nasal spray.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 7, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Glenmark's partner Hikma launches specialty drug Ryaltris in US
Ryaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. Glenmark developed the drug, while Hikma will commercialise it in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 30, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Nasonex 24HR Allergy (mometasone furoate) Nasal Spray for OTC Use
DUBLIN, March 17, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 17, 2022 Category: Drugs & Pharmacology Source Type: news
FDA Approves Ryaltris (mometasone and olopatadine) Nasal Spray for Seasonal Allergic Rhinitis
Mumbai (Maharashtra) [India], January 14, 2022 (ANI/PRNewswire) -- Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company announced that its fully owned subsidiary Glenmark Specialty S.A. (Switzerland), received... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 14, 2022 Category: Drugs & Pharmacology Source Type: news
Class 4 Medicines Defect Information: Mometasone Furoate 50 Microgram / Dose Nasal Spray, Suspension
There is an error relating to the wording on the outer carton label for Mometasone Furoate 50 Microgram / Dose Nasal Spray, supplied by PilsCo Ltd.
Further information and advice for healthcare profe (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 1, 2021 Category: Drugs & Pharmacology Source Type: news
Fixed-combination indacaterol acetate, glycopyrronium, mometasone cost effective for adults with poorly controlled asthma in Italy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news
FDA approves Xolair ® (omalizumab) for adults with nasal polyps
Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Investor Update - December 1, 2020 Category: Pharmaceuticals Source Type: news
FDA approves Xolair ® (omalizumab) for adults with nasal polyps
Basel, 01 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.1 Nasal polyps can lead to a loss of smell and nasal congestion, and frequently co-occur with other respiratory conditions, such as allergies and asthma. With this approval, Xolair is now the first biologic for the treatment ...
Source: Roche Media News - December 1, 2020 Category: Pharmaceuticals Source Type: news
Sinuva (Mometasone Furoate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2020 Category: Drugs & Pharmacology Source Type: news
EU Panel Backs Triple Combo Asthma Inhaler With Digital Sensor EU Panel Backs Triple Combo Asthma Inhaler With Digital Sensor
Enerzair Breezhaler combines indacaterol, glycopyrronium, and mometasone and comes with an optional digital sensor that collects data on patient use to support adherence.International Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 6, 2020 Category: Allergy & Immunology Tags: Pulmonary Medicine News Alert Source Type: news
Dulera (mometasone furoate/formoterol fumarate)
Title: Dulera (mometasone furoate/formoterol fumarate)Category: MedicationsCreated: 10/21/2015 12:00:00 AMLast Editorial Review: 8/20/2019 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - August 20, 2019 Category: Respiratory Medicine Source Type: news
mometasone (Elocon)
Title: mometasone (Elocon)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/8/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 8, 2019 Category: Dermatology Source Type: news
New Approval Helps Implanting Propel Mini a Little Bit Easier
Intersect ENT has received a nod from FDA for a new delivery system to use for its sinus implant. The Menlo Park, CA-based company said the approval was for its Straight Delivery System for use to place the Propel Mini steroid releasing sinus implant in the ethmoid sinus.
PROPEL Mini helps maintain the sinus opening while delivering mometasone furoate directly where it is needed, improving outcomes of frontal (behind the forehead) and ethmoid (behind the bridge of the nose) sinus surgery. The new SDS is designed to help physicians achieve precise and easy delivery of the PROPEL Mini implant to the ethmoid sinus. The compan...
Source: MDDI - July 29, 2019 Category: Medical Devices Authors: MDDI Staff Tags: Implants Source Type: news
